🍽️ terbutaline hemisulfate,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of terbutaline hemisulfate,(prescription) On Probiotics

Rank Probiotic Impact
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by terbutaline hemisulfate,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Lacticaseibacillus genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Agathobacter rectalis species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of terbutaline hemisulfate,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 0.2 0.2
Alzheimer's disease 0.6 -0.6
Ankylosing spondylitis 0.2 0.2
Anorexia Nervosa 0.2 -0.2
Antiphospholipid syndrome (APS) 0.2 0.2
Atrial fibrillation 0.4 0.4
Autism 0.2 0.6 -2
Barrett esophagus cancer 0.2 -0.2
Carcinoma 0.2 0.2
Celiac Disease 0.2 0.2
Cerebral Palsy 0.2 0.2
Chronic Fatigue Syndrome 0.7 0.2 2.5
Chronic Kidney Disease 0.4 -0.4
Chronic Obstructive Pulmonary Disease (COPD) 0.6 0.6
Chronic Urticaria (Hives) 0.2 0.2
Coagulation / Micro clot triggering bacteria 0.2 0.2 0
Colorectal Cancer 0.4 0.2 1
Coronary artery disease 0.2 0.2
COVID-19 0.2 1.2 -5
Crohn's Disease 0.4 -0.4
deep vein thrombosis 0.2 -0.2
Depression 1.3 1.5 -0.15
Dermatomyositis 0.2 0.2
Eczema 0.6 -0.6
Endometriosis 0.2 0.2
Epilepsy 0.2 0.2
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.2 -0.2
Glioblastoma 0.2 -0.2
Halitosis 0.2 -0.2
Hidradenitis Suppurativa 0.2 0.2
Histamine Issues,Mast Cell Issue, DAO Insufficiency 0.2 0.2 0
hypertension (High Blood Pressure 0.2 0.2 0
Inflammatory Bowel Disease 0.6 0.6 0
Insomnia 0.2 0.2
Liver Cirrhosis 0.2 0.2 0
Long COVID 0.4 0.2 1
ME/CFS with IBS 0.2 0.2
ME/CFS without IBS 0.3 0.3
Metabolic Syndrome 0.2 0.2 0
Mood Disorders 1.3 1.5 -0.15
multiple chemical sensitivity [MCS] 0.6 0.6
Multiple Sclerosis 0.6 0.6 0
Neuropathy (all types) 0.2 0.2
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.2 0.4 -1
Obesity 0.2 1.1 -4.5
obsessive-compulsive disorder 0.2 0.2 0
Osteoarthritis 0.2 0.2
pancreatic cancer 0.2 0.2
Parkinson's Disease 0.2 0.4 -1
Psoriasis 0.2 0.2
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.2 0.2
Sjögren syndrome 0.2 0.2 0
Small Intestinal Bacterial Overgrowth (SIBO) 0.2 0.2
Systemic Lupus Erythematosus 0.2 0.2
Type 1 Diabetes 0.2 -0.2
Type 2 Diabetes 0.2 0.2 0
Ulcerative colitis 0.6 0.6
Unhealthy Ageing 0.2 0.4 -1

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.


The awesome web hosting site that we use. Try it if you need to host (or unhappy with current provider)